Incidence and treatment of hemophagocytic lymphohistiocytosis in hospitalized children with Ehrlichia infection

Stephanie S. Cabler, Patrick G. Hogan, Stephanie A. Fritz, Jeffrey J. Bednarski, David A. Hunstad

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

We report a large cohort of pediatric patients with human monocytic ehrlichiosis (HME), enabling an estimated incidence of secondary hemophagocytic lymphohistiocytosis (HLH) in hospitalized children with HME. Among 49 children with PCR-confirmed Ehrlichia infection, 8 (16%) met current criteria for HLH. Those with HLH had more significant hematologic abnormalities and longer durations from symptom onset to admission and definitive anti-infective therapy. Among these eight, three received chemotherapy plus doxycycline, one of whom died; the other five were treated with doxycycline without chemotherapy, and all survived without HLH recurrence. Our findings demonstrate that antimicrobial therapy alone can successfully resolve Ehrlichia-associated HLH.

Original languageEnglish
Article numbere28436
JournalPediatric Blood and Cancer
Volume67
Issue number10
DOIs
StatePublished - Oct 1 2020

Keywords

  • Ehrlichia
  • doxycycline
  • hemophagocytic lymphohistiocytosis
  • hyperferritinemia

Fingerprint

Dive into the research topics of 'Incidence and treatment of hemophagocytic lymphohistiocytosis in hospitalized children with Ehrlichia infection'. Together they form a unique fingerprint.

Cite this